FDA Approves Palbociclib with Trastuzumab for HR-positive, HER2-positive Breast Cancer
The FDA has approved palbociclib in combination with trastuzumab, with or without pertuzumab, for maintenance treatment in HR-positive, HER2-positive metastatic breast cancer.